Navigation Links
Baxter Raises Full-Year 2008 Outlook Following Strong Second-Quarter Financial Results
Date:7/17/2008

(TT) business

were previously reported in the BioScience business. The TT business

was sold on February 28, 2007. The TT totals above include sales of

TT products through the date of divestiture, as well as revenues

associated with manufacturing, distribution and other services

provided by the company to the buyer of the TT business post-

divestiture.

Baxter International Inc.

Key Product Line Sales

Periods Ending June 30, 2008 and 2007

(unaudited)

($ in millions)

--------------------------------------------------------------------------

% Growth % Growth

@ @

Q2 Q2 Actual Constant

2008 2007 Rates Rates

--------------------------------------------------------------------------

--------------------------------------------------------------------------

BioScience

Recombinants $508 $431 18% 10%

Plasma Proteins 291 243 20% 12%

Antibody Therapy 315 238 32% 27%

Regenerative Medicine (1) 109 87 25% 17%

Other (2) 162 191 (15%) (27%)

--------------------------------------------------------------------------

Total BioScience (3) $1,385 $1,190 16% 8%

--------------------------------------------------------------------------

--------------------------------------------------------------------------'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related biology technology :

1. Bioniche Pharma Acquires Baxters ENLON(R) and ENLON-PLUS(R)
2. Baxters Board of Directors Declares Quarterly Dividend
3. Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook
4. Baxters V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals
5. Baxter Announces FDA Approval of ARTISS Slow-Setting Fibrin Sealant in Treatment of Burn Patients
6. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
7. Baxter and Its Foundation Contribute Nearly $53 Million in 2007 to Address Critical Needs Locally and Globally
8. Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products
9. Baxter Declares Quarterly Dividend
10. Baxter Provides Update on Heparin Reactions
11. Baxters Costa Rica Facility Recognized With Shingo Prize for Excellence in Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014  Pfenex Inc. (NYSE MKT: PFNX), a ... high-value and difficult to manufacture proteins including biosimilar ... financial results for the second quarter ended June ... of our initial public offering, we have the ... candidates, derived from our proprietary protein expression platform," ...
(Date:8/29/2014)... circuits are based on electrons, but one of the ... circuits, i.e. circuits based on light (photons) instead of ... create a stream of single photons and control their ... of attempts to achieve this control, but now scientists ... a steady stream of photons emitted one at a ...
(Date:8/29/2014)... New York (PRWEB) August 29, 2014 ... valued at $5.6 billion in 2019. It is ... from 2013 to 2019, and was valued at ... report published by Transparency Market Research. , For ... visit: http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research report, ...
(Date:8/29/2014)... 2014 According to a new market report ... orthobiologics market was valued at USD 3,754.6 million in 2012 ... in 2019at a CAGR of 5.9% from 2013 to 2019. ... above is afflicted by bone and joint disorders, and this ... This has and will continue to increase the demand for ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Breakthrough in light sources for new quantum technology 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
... MONTVALE, N.J., May 13 Synvista Therapeutics,Inc. (Amex: ... a 160-patient Phase 2 study,of alagebrium in patients with ... A.G.E. [Advanced Glycation End Product],Breaker Alagebrium in Diastolic Heart ... the effect of six months,of oral treatment with 400mg ...
... Yields First Milestone, NEW YORK, May 13 ... pre-disease collection, processing and long-term,storage of adult stem cells ... been secured for a new stem cell collection center ... Smith, MD MBA, NeoStem,s Chairman and Chief Executive Officer,commented: ...
... May 13 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: ... biopharmaceutical company focused on,endocrine therapy and oncology, ... Phase 2 study of subcutaneously,administered LHRH antagonist ... (BPH", has been accepted for publication in ...
Cached Biology Technology:Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure 2Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure 3Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure 4NeoStem to Expand Stem Cell Collection Center Network to Florida 2NeoStem to Expand Stem Cell Collection Center Network to Florida 3AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 2AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 3AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 4AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 5AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 6
(Date:8/29/2014)... surprising discoveries about the body,s initial responses to ... team found that specialized cells in the intestine ... invasion and are the source of gut inflammation ... , Though aimed at the presence of ... that provides a barrier to protect the body ...
(Date:8/29/2014)... 29, 2014) Scientists at the Barshop Institute for ... Medicine at the UT Health Science Center at San ... tissues of the longest-lived rodent, the naked mole rat. ... cells of naked mole rats protects and alters the ... and obsolete proteins. , The factor also protects proteasome ...
(Date:8/29/2014)... has been known about what genetic changes transform wild ... one of whom is a University of Montana assistant ... controlling the development of the brain and the nervous ... was published Aug. 28 in Science and ... at http://www.sciencemag.org/ ., The domestication of animals and ...
Breaking Biology News(10 mins):The early cost of HIV 2Factor in naked mole rat's cells enhances protein integrity 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3
... which they can pass on to humans. But now research ... Research says that pigs get HEV early enough to minimise ... worry about would occur if the infection rate in pigs ... chance pigs will pass on HEV to humans at slaughter. ...
... Dr Pep Canadell, from the Global Carbon Project and CSIRO ... that tropical deforestation releases 1.5 billion tonnes of carbon each ... accounts for nearly 20 per cent of carbon emissions due ... estimated 87 to 130 billion tonnes of carbon by 2100, ...
... grazing normally on algae in the rocky intertidal zone of ... by a parasite. But the better news is, according to ... might have more to eat if plenty of your neighbors ... of the National Academy of Sciences Early Edition ( http://www.pnas.org/papbyrecent.shtml ...
Cached Biology News:Confirmed -- deforestation plays critical climate change role 2Parasites' impact goes beyond host to affect ecosystem 2Parasites' impact goes beyond host to affect ecosystem 3
Purified Mouse anti-Hu p120 Catenin (pT916) Storage Temperature: Refrigerate(2 to 8C)...
Request Info...
ROCK-1 (cleaved) Monoclonal Ab 100 ug purified mouse monoclonal antibody. Clone# 12M03. Reacts with human. Tested in Western blot analysis....
Anti-Cullin-1 Host: rabbit polyclonal Species Reactivity: human, mouse Applications: IHC(P), WB, IP Storage: 4C...
Biology Products: